LYG:NYSELloyds Banking Group Plc Analysis
Data as of 2026-05-22 - not real-time
$5.41
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Lloyds Banking Group (LYG) is trading at $5.41, comfortably above the computed support level of $5.03 and below the resistance of $5.50, giving an estimated upside of roughly 9%. The short‑term trend is bullish, with the 20‑day SMA ($5.29) sitting just above the 50‑day SMA ($5.27) and both above the 200‑day SMA ($5.06), while the RSI of 54 signals neutral momentum and the MACD histogram is positive, reinforcing the bullish signal. Volume is on an increasing trajectory, and the market’s fear‑greed index is at an “Extreme Greed” level (90.86), suggesting strong investor appetite.
Fundamentally, LYG trades at a PE of 13.2, notably below the industry average of 16.7, indicating relative undervaluation despite a high price‑to‑book of 5.75. The dividend yield of 3.7% with a payout ratio under 45% appears sustainable given the firm’s massive cash reserves exceeding its debt. Recent earnings beat, with Q1 net income of $1.9 bn and a 17% ROE, prompted UBS to upgrade the stock to “Buy” and raise the price target to $6.47, aligning with analyst consensus of a modest upside. However, the stock exhibits elevated risk markers: 30‑day volatility of 34% and a beta around 1.3 point to higher price swings, while the historical max drawdown of –22.7% underscores downside potential.
Fundamentally, LYG trades at a PE of 13.2, notably below the industry average of 16.7, indicating relative undervaluation despite a high price‑to‑book of 5.75. The dividend yield of 3.7% with a payout ratio under 45% appears sustainable given the firm’s massive cash reserves exceeding its debt. Recent earnings beat, with Q1 net income of $1.9 bn and a 17% ROE, prompted UBS to upgrade the stock to “Buy” and raise the price target to $6.47, aligning with analyst consensus of a modest upside. However, the stock exhibits elevated risk markers: 30‑day volatility of 34% and a beta around 1.3 point to higher price swings, while the historical max drawdown of –22.7% underscores downside potential.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Bullish technical alignment (SMA crossover, MACD histogram positive)
- Positive earnings surprise and UBS upgrade to Buy
- Attractive upside relative to current price and strong dividend yield
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- Undervalued PE versus peers with solid earnings growth
- Sustainable dividend supporting total return
- Elevated volatility and beta suggesting cautious positioning
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Fundamental strength: low PE, high cash, manageable debt
- Consistent dividend income and payout ratio below 50%
- Long‑term banking fundamentals and upside potential toward analyst targets
Key Metrics & Analysis
Financial Health
Revenue Growth11.50%
Profit Margin26.50%
P/E Ratio13.2
ROE10.78%
ROA0.55%
P/B Ratio5.8
Industry P/E16.7
Technical Analysis
TrendBullish
RSI54.3
Support$5.03
Resistance$5.50
MA 20$5.29
MA 50$5.27
MA 200$5.06
MACDBullish
VolumeIncreasing
Fear & Greed Index90.86
Valuation
Target Price$5.92
Upside/Downside9.43%
GradeUndervalued
TypeBlend
Dividend Yield3.70%
Risk Assessment
Beta1.30
Volatility34.21%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.